Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Buy
52
NBIX Quote, Financials, Valuation and Earnings
Last price:
$122.87
Seasonality move
:
-5.2%
Day range:
$135.02 - $139.83
52-week range:
$84.23 - $160.18
Dividend yield:
0%
P/E ratio:
32.82x
P/S ratio:
5.24x
P/B ratio:
4.56x
Volume:
1.4M
Avg. volume:
1.1M
1-year change:
17.62%
Market cap:
$13.7B
Revenue:
$2.4B
EPS (TTM):
$4.19
Analysts' Opinion
-
Consensus RatingNeurocrine Biosciences, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 19 Buy ratings, 4 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $179.59, Neurocrine Biosciences, Inc. has an estimated upside of 30.67% from its current price of $137.44.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $147.00 representing 100% downside risk from its current price of $137.44.
Fair Value
-
According to the consensus of 23 analysts, Neurocrine Biosciences, Inc. has 30.67% upside to fair value with a price target of $179.59 per share.
NBIX vs. S&P 500
-
Over the past 5 trading days, Neurocrine Biosciences, Inc. has underperformed the S&P 500 by -0.44% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Neurocrine Biosciences, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Neurocrine Biosciences, Inc. has grown year-over-year revenues for 17 quarters straight. In the most recent quarter Neurocrine Biosciences, Inc. reported revenues of $794.9M.
Earnings Growth
-
Neurocrine Biosciences, Inc. has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Neurocrine Biosciences, Inc. reported earnings per share of $2.04.
Enterprise value:
13.1B
EV / Invested capital:
--
Price / LTM sales:
5.24x
EV / EBIT:
23.61x
EV / Revenue:
4.87x
PEG ratio (5yr expected):
2.70x
EV / Free cash flow:
22.03x
Price / Operating cash flow:
23.69x
Enterprise value / EBITDA:
22.40x
Gross Profit (TTM):
$2.6B
Return On Assets:
11.13%
Net Income Margin (TTM):
15.95%
Return On Equity:
15.8%
Return On Invested Capital:
13.56%
Operating Margin:
30.1%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $1.8B | $2.2B | $2.7B | $622.1M | $794.9M | |
| Gross Profit | $1.7B | $2.2B | $2.6B | $608.5M | $780.9M | |
| Operating Income | $349.6M | $588.3M | $553.6M | $184.8M | $239.3M | |
| EBITDA | $369.6M | $614M | $583.3M | $191.3M | $247M | |
| Diluted EPS | $1.87 | $3.73 | $4.19 | $1.24 | $2.04 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1B | $1.2B | $1.6B | $1.9B | $2.2B | |
| Total Assets | $2B | $2.1B | $2.8B | $3.5B | $4.3B | |
| Current Liabilities | $225.9M | $485.1M | $691.6M | $429.7M | $638M | |
| Total Liabilities | $671.3M | $598.8M | $846.1M | $816.1M | $1.3B | |
| Total Equity | $1.3B | $1.5B | $2B | $2.7B | $3B | |
| Total Debt | $437.1M | $265.8M | $255.8M | $251.4M | $428.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $409.4M | $476.4M | $636.8M | $158M | $227.5M | |
| Cash From Investing | -$380.9M | -$260.3M | -$279.8M | $24.7M | -$196.7M | |
| Cash From Financing | $54.5M | -$161.3M | -$365.6M | $26.4M | $45.6M | |
| Free Cash Flow | $384.7M | $440.1M | $593.1M | $149.9M | $214.3M | |
NBIX
Sector
Market Cap
$13.7B
$23.4M
Price % of 52-Week High
85.8%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
2.34%
-1.64%
1-Year Price Total Return
17.62%
-21.81%
Beta (5-Year)
0.311
0.504
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$138.53
200-day SMA
Buy
Level
$135.46
Bollinger Bands (100)
Sell
Level
136.13 - 148.69
Chaikin Money Flow
Buy
Level
43.5M
20-day SMA
Buy
Level
$136.50
Relative Strength Index (RSI14)
Sell
Level
48.11
ADX Line
Sell
Level
15.54
Williams %R
Neutral
Level
-53.426
50-day SMA
Sell
Level
$142.07
MACD (12, 26)
Sell
Level
-0.38
25-day Aroon Oscillator
Buy
Level
60
On Balance Volume
Neutral
Level
75.2M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (7.9895)
Buy
CA Score
(Annual)
Level (1.3313)
Buy
Beneish M-Score
(Annual)
Level (-2.5662)
Buy
Momentum Score
Level (5)
Buy
Ohlson Score
Level (-2.4721)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.
Stock Forecast FAQ
In the current month, NBIX has received 19 Buy ratings 4 Hold ratings, and 0 Sell ratings. The NBIX average analyst price target in the past 3 months is $179.59.
-
Where Will Neurocrine Biosciences, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Neurocrine Biosciences, Inc. share price will rise to $179.59 per share over the next 12 months.
-
What Do Analysts Say About Neurocrine Biosciences, Inc.?
Analysts are divided on their view about Neurocrine Biosciences, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Neurocrine Biosciences, Inc. is a Sell and believe this share price will drop from its current level to $147.00.
-
What Is Neurocrine Biosciences, Inc.'s Price Target?
The price target for Neurocrine Biosciences, Inc. over the next 1-year time period is forecast to be $179.59 according to 23 Wall Street analysts, 19 of them rate the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.
-
Is NBIX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Neurocrine Biosciences, Inc. is a Buy. 19 of 23 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of NBIX?
You can purchase shares of Neurocrine Biosciences, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Neurocrine Biosciences, Inc. shares.
-
What Is The Neurocrine Biosciences, Inc. Share Price Today?
Neurocrine Biosciences, Inc. was last trading at $122.87 per share. This represents the most recent stock quote for Neurocrine Biosciences, Inc.. Yesterday, Neurocrine Biosciences, Inc. closed at $137.44 per share.
-
How To Buy Neurocrine Biosciences, Inc. Stock Online?
In order to purchase Neurocrine Biosciences, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get NBIX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
NBIX
Sector
P/E ratio
32.82x
23.34x
PEG ratio
2.70x
-0.01x
P/B ratio
4.56x
1.72x
Price / LTM sales
5.24x
1.51x
Growth Metrics
NBIX
Sector
Revenue growth
27.78%
3.21%
Earnings growth
64.24%
10.12%
Revenue (5-year growth)
24.48%
6.27%
Earnings forecast
$2.30
-$0.19
Profitability
NBIX
Sector
Profitability FY 2024
$2.3B
$2.7M
Return on invested capital
13.56%
-33.62%
Return on assets
11.13%
-29.68%
Return on equity
15.8%
-38.89%
Earnings Date
Last Earnings Date
Feb
11
Next Earnings Date
Feb
13
Estimated Next Earnings Date
May
15
Balance Sheet
NBIX
Sector
Total cash
$1.1B
$25M
Short term investments
$843.1M
$23.9M
Total assets
$3.8B
$72.8M
Long term debt
$428.4M
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
40
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
91
TDC alert for Feb 12
Teradata Corp. [TDC] is down 11.64% over the past day.
Buy
67
DIOD alert for Feb 12
Diodes, Inc. [DIOD] is down 7.63% over the past day.
Buy
77
VRT alert for Feb 12
Vertiv Holdings Co. [VRT] is down 4.79% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
